Escitalopram, sertraline and venlafaxine in the pharmacotherapy of depression – selection based on an adaptation of the profile of the drug to the patient’s profile Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2016

Main Article Content

Sławomir Murawiec
Specjalistyczna Poradnia Depresji NZOZ Centrum Terapii DIALOG

Abstract

Personalized selection of treatment of depression may allow for more effective treatment of the disease of an individual patient. The work focuses on three commonly used antidepressants: escitalopram, sertraline, and venlafaxine. Their practical application is discussed in the context of the profiles of patients that may respond to therapy with each of these compounds. The paper discusses the choice of antidepressant in the context of both the clinical experience with the drug, and evidence-based medicine as well as the individual characteristics of patients, their life history, dynamics of symptoms formation, clinical picture of depressive episode, psychological aspects of contact with the doctor and response to treatment.

Article Details

How to Cite
Murawiec , S. (2016). Escitalopram, sertraline and venlafaxine in the pharmacotherapy of depression – selection based on an adaptation of the profile of the drug to the patient’s profile. Medycyna Faktow (J EBM), 9(4(33), 300-306. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2202
Issue
Vol 9 No 4(33) (2016)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Łoza B.: Escitalopram: odkrycie leku i jego rozwój. Neuropsychiatria. Przegląd Kliniczny 2011; 3: 5-14.
2. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
3. Wierzbiński P.: Farmakoterapia depresji – na co zwrócić uwagę. W: Murawiec S., Wierzbiński P.: Depresja 2016. Via Medica, Gdańsk 2016.
4. Rybakowski J., Borkowska A.: Escitalopram – druga generacja inhibitorów transportera serotoniny? Psychiatr. Pol. 2004; 37: 227-239.
5. Murawiec S.: Escitalopram – lek przeciwdepresyjny będący allosterycznym inhibitorem wychwytu zwrotnego serotoniny (ASRI). Lek w Polsce 2005; 9(207): 21-29.
6. Murawiec S.: Selektywne inhibitory wychwytu zwrotnego serotoniny a zmiana cech osobowości i relacji intymnych. Psychiatr. Dypl. 2016; 13(2): 12-18.
7. Tang T.Z., DeRubeis R.J., Hollon S.D. et al.: Personality change during depression treatment: A Placebo-Controlled Trial. Arch. Gen. Psychiatry 2009; 66(12): 1322-1330.
8. Tse W.S., Bond A.J.: Serotonergic intervention affects both social dominance and affiliative behavior. Psychopharmacology 2002; 161: 324-330.
9. Young S.N., Moskowitz D.S., aan het Rot M.: Possible role of more positive social behavior in the clinical effects of antidepressant drugs. J. Psychiatry Neurosci. 2014; 39: 60-65.
10. Shapiro P.A., Lesperance F., Frasure-Smith N. et al.: An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am. Heart J. 1999; 137(6): 1100-1106.
11. Glassman A.H., O’Connor C.M., Califf R.M.; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group: Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288(6): 701-709.
12. Bazire S.: Przewodnik leków psychotropowych. Via Medica, Gdańsk 2014: 249.
13. Kennedy S.H., Gorwood P.: Successful management of major depressive disorder. Future Medicine Ltd, London 2014: 37.
14. Siwek M.: Leki przeciwdepresyjne w terapii bólu. W: Dudek D.: Ból i depresja. Termedia, Poznań 2011: 141-166.